RxDoctor Payments Data

Brian Brown, MD

Ophthalmology · Downey, CANPI 1992748479

Payments from drug & device makers

$1,545in general payments, 2019–2025

Across 18 payments — averaging $85.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$1K
  • Optovue, Inc.$74
  • Alcon$70
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60
  • Ocular Therapeutix, Inc.$60
  • Rxsight Inc$22
  • plus $35 from 2 others

What the payments were for

  • Travel & lodging$1,09171%
  • Food & beverage$36123%
  • Education$745%
  • Entertainment$191%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,545 in reported general payments places this provider in the 50th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$257,550
Medicare patients
512
Services billed
2,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost196$86,761
RestasisCyclosporine36$39,605
Restasis MultidoseCyclosporine50$32,953
Cyclosporine65$24,637
Timolol Maleate92$8,545
Prednisolone Acetate255$6,599
RhopressaNetarsudil Mesylate14$5,664
Latanoprost332$3,809
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat210$3,617
Tobramycin-DexamethasoneTobramycin/Dexamethasone76$2,944
Brimonidine Tartrate48$2,901
SimbrinzaBrinzolamide/Brimonidine Tart11$2,216
Ketorolac Tromethamine219$2,021
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$1,877
Ofloxacin194$1,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$70$2,21611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →